[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022004258A - Entrega transdermica de cannabidiol. - Google Patents

Entrega transdermica de cannabidiol.

Info

Publication number
MX2022004258A
MX2022004258A MX2022004258A MX2022004258A MX2022004258A MX 2022004258 A MX2022004258 A MX 2022004258A MX 2022004258 A MX2022004258 A MX 2022004258A MX 2022004258 A MX2022004258 A MX 2022004258A MX 2022004258 A MX2022004258 A MX 2022004258A
Authority
MX
Mexico
Prior art keywords
cannabidiol
transdermal delivery
transdermal
inflammation
pain
Prior art date
Application number
MX2022004258A
Other languages
English (en)
Inventor
Marina Borovinskaya
Nisarg Modi
Tamanna Lather
Fotios M Plakogiannis
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of MX2022004258A publication Critical patent/MX2022004258A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un sistema de administración transdérmica de fármacos que comprende cannabidiol o su sal solo o en combinaciones de los mismos. La administración transdérmica puede proporcionar una concentración plasmática de fármaco a una velocidad predeterminada durante un período de tiempo predeterminado con un régimen terapéutico simplificado al disminuir la frecuencia de dosificación para el tratamiento y/o la prevención del dolor y/o la inflamación.
MX2022004258A 2019-10-14 2020-10-13 Entrega transdermica de cannabidiol. MX2022004258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962914662P 2019-10-14 2019-10-14
PCT/IB2020/059608 WO2021074790A1 (en) 2019-10-14 2020-10-13 Transdermal delivery of cannabidiol

Publications (1)

Publication Number Publication Date
MX2022004258A true MX2022004258A (es) 2022-05-26

Family

ID=75382383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004258A MX2022004258A (es) 2019-10-14 2020-10-13 Entrega transdermica de cannabidiol.

Country Status (8)

Country Link
US (1) US12097293B2 (es)
EP (1) EP4045024A4 (es)
JP (1) JP2022551730A (es)
CN (1) CN114555068A (es)
AU (1) AU2020366147B2 (es)
CA (1) CA3155181A1 (es)
MX (1) MX2022004258A (es)
WO (1) WO2021074790A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
MX2023006561A (es) * 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
AU2022255944A1 (en) * 2021-04-08 2023-10-12 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2022219468A1 (en) * 2021-04-12 2022-10-20 Pike Therapeutics, Inc. 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
EP4098254A1 (en) * 2021-06-04 2022-12-07 Assistance Publique, Hopitaux De Paris Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
WO2024069613A1 (en) * 2022-09-30 2024-04-04 Atomix Pharmaceuticals Inc. Compositions and methods for the treatment of temporomandibular joint disorder

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6328992B1 (en) 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
EP1109533A1 (en) 1999-07-08 2001-06-27 Orlando Hung Pulmonary delivery of liposome-encapsulated cannabinoids
US20050042271A1 (en) 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
JP2003524652A (ja) 2000-02-29 2003-08-19 ツァン，ツィエ 改良された経皮薬剤パッチ
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
AU1436402A (en) * 2000-11-06 2002-05-15 Samyang Corp Transdermal drug delivery system with improved water absorbability and adhesion properties
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20180042842A1 (en) 2001-02-14 2018-02-15 Gw Pharma Limited Pharmaceutical formulations
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
CH695661A5 (de) 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
PT2314284T (pt) 2002-08-14 2017-05-25 Gw Pharma Ltd Formulações líquidas de canabinoide para administração mucosal
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
WO2004100893A2 (en) 2003-05-12 2004-11-25 Indevus Pharmaceuticals, Inc. Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
EP1559423A1 (en) 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7671052B2 (en) 2004-10-05 2010-03-02 Adolor Corporation Phenyl derivatives and methods of use
WO2006044645A2 (en) 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use
US7968594B2 (en) 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2431105A (en) 2005-10-12 2007-04-18 Gw Pharma Ltd Cannabinoids for the treatment of pulmonary disorders
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US7544676B2 (en) 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US8481085B2 (en) 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2008006226A1 (en) 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica
BRPI0715328A2 (pt) 2006-08-04 2013-07-09 Insys Therapeutics Inc formulaÇço, e, dispositivo de dose unitÁria ou de dose méltipla para a administraÇço sublingual de uma droga
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
CA2664935A1 (en) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
WO2008063625A2 (en) 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
CN101815697A (zh) 2007-07-30 2010-08-25 奥特兰兹公司 大麻二酚前药、包括大麻二酚前药的组合物及其使用方法
US20090181080A1 (en) 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2460672B (en) 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
CN105456181A (zh) 2008-06-19 2016-04-06 Lts罗曼治疗方法有限公司 阳离子活性剂透皮输运组合物
EP2309993A1 (en) 2008-06-25 2011-04-20 US Worldmeds LLC Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
JP5801794B2 (ja) 2009-04-28 2015-10-28 ジネルバ ファーマシューティカルズ， インコーポレイティド カンナビジオールの製剤及びその使用方法
CA2760128A1 (en) 2009-04-29 2010-11-04 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
LT2473475T (lt) 2009-08-31 2017-08-10 Zynerba Pharmaceuticals, Inc. Kanabidiolio provaisto panaudojimas vietiniam arba transderminiam įvedimui su mikroadatomis
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
EP2650019B1 (en) 2010-12-07 2015-08-05 Yutoku Pharmaceutical Industries Co., Ltd. Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
US8642645B2 (en) 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
WO2013009928A1 (en) 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
US20130022687A1 (en) 2011-07-19 2013-01-24 Fitzgerald Jr John James Topical transdermal method for delivering nutrients through the skin for expedited wound healing
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
US20140348926A1 (en) 2012-01-19 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulation and method for increasing oral bioavailability of drugs
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
US9763912B2 (en) 2013-10-30 2017-09-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions, methods of use, and methods of treatment
US10064905B1 (en) 2013-11-11 2018-09-04 Ilysm, LLC Pharmaceutical preparation
US10555927B2 (en) 2013-11-11 2020-02-11 Ilysm, LLC Compositions and methods for enhancing sexual pleasure and performance
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
WO2015140736A1 (en) 2014-03-18 2015-09-24 Izun Pharmaceuticals Corp. Protein-bound cannabinoid compositions
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
CN114191420A (zh) 2014-05-29 2022-03-18 雷迪厄斯制药公司 稳定的大麻素类化合物制剂
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
ES2898173T3 (es) 2014-06-30 2022-03-04 Syqe Medical Ltd Dispositivos y sistemas para la administración pulmonar de principios activos
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2016004121A1 (en) 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
US20160039591A1 (en) 2014-07-22 2016-02-11 Craig E. Kinzer Packaging systems, devices, methods, and composition including cannabinoid unit dose forms
EP3217995A1 (en) 2014-08-25 2017-09-20 Janing Holding ApS Device with compositions for delivery to the lungs, the oral mucosa and the brain
CA2859930A1 (en) 2014-09-22 2016-03-22 Antony Paul Hornby A cannabis topical from heat treated cocount oil
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB201418713D0 (en) 2014-10-21 2014-12-03 Kymab Ltd Bindings Proteins
JP6676062B2 (ja) 2014-11-03 2020-04-08 ラモト アト テルーアビブ ユニバーシティー リミテッド 認知低下を処置するための方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
WO2016092539A1 (en) 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
AU2015101908A4 (en) 2014-12-21 2019-05-02 One World Cannabis Ltd Cannabis-based extracts and topical formulations for use in skin disorders
WO2016109624A1 (en) 2014-12-30 2016-07-07 University Of Houston System Pharmaceutical compositions
WO2016126592A1 (en) 2015-02-02 2016-08-11 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
BR112017018944A2 (pt) 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
US20180036303A1 (en) 2015-03-10 2018-02-08 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease
AU2016231788A1 (en) 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
BR112018001310A2 (pt) 2015-07-22 2018-09-11 Phytopharma Int Ltd composições ingeríveis por abelha, métodos de uso das mesmas para a produção de mel e mel produzido por estas
US9827282B2 (en) 2015-07-24 2017-11-28 Bao Tran Medication dispensing system
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2995418A1 (en) 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
US10272125B2 (en) 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
EP3355874A4 (en) 2015-09-30 2019-06-12 George Edward Hoag TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF
US10695287B2 (en) 2015-11-17 2020-06-30 Cersci Therapeutics, Inc. AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same
US20170202895A1 (en) 2016-01-18 2017-07-20 Kevin Anthony Hugh Cannabis Pellets
US10338355B2 (en) 2016-02-05 2019-07-02 Largan Precision Co., Ltd. Lens assembly
IL307857A (en) 2016-03-16 2023-12-01 Buzzelet Development And Technologies Ltd Cannobinoid compounds are rich in terpenes
CN109069459A (zh) 2016-04-12 2018-12-21 哈比制药私人有限公司 脂质体制剂和治疗方法
LT6486B (lt) 2016-04-13 2018-01-10 UAB "SatiMed" Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
US11839601B2 (en) 2016-04-19 2023-12-12 Canna-B Cure Ltd Cannabis-enriched enzymatically treated therapeutic composition
EP3928776A1 (en) 2016-04-22 2021-12-29 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
BR112018077541A2 (pt) 2016-07-11 2019-04-30 Intec Pharma Ltd. formulações orais gastrorretentivas e usos das mesmas
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10869842B1 (en) 2016-09-07 2020-12-22 David P Summers Transdermal delivery of pharmaceutical agents
NZ751690A (en) 2016-09-07 2022-02-25 Glia Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
AU2017341707A1 (en) 2016-10-12 2019-04-11 Columbia Care Llc An oral composition of extracted cannabinoids and methods of use thereof
US20190314297A1 (en) 2016-11-02 2019-10-17 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
US20190321426A1 (en) 2016-11-02 2019-10-24 Tikun Olam Ltd Combination therapies with cannabis plant extract
WO2018085794A1 (en) 2016-11-07 2018-05-11 Avidas Pharmaceuticals Llc Therapeutic cannabinoid formulations and methods for their use
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2018106108A1 (en) 2016-12-06 2018-06-14 KEPPEL HESSELING, Jan Marius Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
WO2018112138A1 (en) 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
WO2018126225A1 (en) 2016-12-29 2018-07-05 International Bioceutical Company, Llc Modular transdermal delivery system and associated methods of manufacture and use
US20180311181A1 (en) 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety
US20180311180A1 (en) 2016-12-29 2018-11-01 International Bioceutical Co. LLC Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
US10675264B2 (en) 2017-02-07 2020-06-09 Elevate Technologies Llc Terpene-based compositions, methods of preparations and uses thereof
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN111093633A (zh) 2017-05-26 2020-05-01 奥特姆医药公司 双相大麻素递送
US10945967B2 (en) 2017-05-30 2021-03-16 Jae Wang. Song Formulations of a transdermal patch for pain management
EP3630145A4 (en) 2017-05-31 2021-04-07 Phytecs, Inc. PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM
WO2019002926A1 (en) 2017-06-27 2019-01-03 Enviro BioMedical Laboratories Inc. MIXTURE-TYPE CANNABIS COMPOUNDS AND PROCESSES FOR PREPARING THE SAME
EP3644976A4 (en) 2017-06-28 2021-03-24 Buzzelet Development And Technologies Ltd TERPEN-ENRICHED CANNABINOID PRODUCT FOR WOMEN'S HEALTH
CA3013573A1 (en) 2017-08-08 2019-02-08 Steven Bermudez Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process
CA3071497A1 (en) 2017-08-13 2019-02-21 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition and method of treatment
MX2020001768A (es) 2017-08-14 2020-12-03 Zynerba Pharmaceuticals Inc Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
EP3675849A4 (en) 2017-09-02 2021-11-24 Scientific Holdings, LLC TETRAHYDROCANNABINOL MODULATORS
CN109498606A (zh) 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
AU2018337933A1 (en) 2017-09-19 2020-03-12 Zynerba Pharmaceuticals, Inc. Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
US20200289458A1 (en) 2017-09-22 2020-09-17 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
CA3077330A1 (en) 2017-09-28 2019-04-04 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome with cannabidiol
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
SG11202003505RA (en) 2017-10-17 2020-07-29 Remy Biosciences Inc Improved delivery systems for moieties including cbd enhanced combinations, formulations and chimeras
US10307392B2 (en) 2017-10-21 2019-06-04 Alexander Kariman Compound and method for treatment of diseases and disorders
US20200345655A1 (en) 2017-11-15 2020-11-05 The Regents Of The University Of California Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain
WO2019130215A1 (en) 2017-12-27 2019-07-04 To Pharmaceuticals Llc Cannabis compositions for the treatment of inflammatory skin disorders
US10722545B2 (en) 2018-01-01 2020-07-28 Alexander Kariman Compound and method for treatment of movement disorders
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
EP3737360A1 (en) 2018-01-12 2020-11-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery
US11759473B2 (en) 2018-02-16 2023-09-19 American Nano, LLC Topical compositions incorporating silica fibers
US11684604B2 (en) 2018-02-23 2023-06-27 Yuzu Lv Llc Cannabis based therapeutic and method of use
AU2018417229A1 (en) 2018-04-04 2020-10-15 Vinsan Therapeutics Inc. Topical cannabinoid formulations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
EP3781140A4 (en) 2018-04-14 2022-07-13 Buzzelet Development And Technologies Ltd TERPENE-ENRICHED CANNABINOID COMPOSITION FOR THE TREATMENT OF DISEASES AND/OR SYMPTOMS RELATED TO A STRESSING EVENT
MX2020011371A (es) 2018-04-27 2021-04-12 Remy Biosciences Inc Nuevos dispositivos medicos, vehiculos de suministro y fabricacion de los mismos.
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US20190328884A1 (en) 2018-04-30 2019-10-31 Chemic Laboratories, Inc. Compositions and methods of their use
US20210196669A1 (en) 2018-05-24 2021-07-01 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
US10864189B2 (en) 2018-06-29 2020-12-15 Jenna Borok Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care
GB201811834D0 (en) 2018-07-19 2018-09-05 Medherant Ltd Patch
GB201811833D0 (en) 2018-07-19 2018-09-05 Medherant Ltd Patch
US20200054887A1 (en) 2018-08-15 2020-02-20 Bruce H. Levin Topical Therapeutics
US10751299B2 (en) 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
CA3060926A1 (en) 2018-09-06 2020-03-06 NuVessl, Inc. Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
IL261774B (en) 2018-09-13 2020-04-30 Unv Medicine Ltd Compositions for treating dermatological conditions
US11357958B2 (en) 2018-10-25 2022-06-14 Medtronic Vascular, Inc. Devices and techniques for cardiovascular intervention
WO2020115751A1 (en) 2018-12-06 2020-06-11 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of alzheimer's disease and dementia
WO2020123625A1 (en) 2018-12-11 2020-06-18 The Regents Of The University Of Michigan Co-crystals, method and apparatus for forming the same
US11458109B2 (en) 2018-12-14 2022-10-04 Zynerba Pharmaceuticals, Inc. Treatment of 22Q11.2 deletion syndrome with cannabidiol
EP3902553A4 (en) 2018-12-27 2022-10-05 Buzzelet Development And Technologies Ltd ENRICHED CANNABINOID COMPOSITION IN HERBAL PREPARATION AND METHOD OF TREATMENT
WO2020136627A1 (en) 2018-12-29 2020-07-02 Buzzelet Development And Technologies Ltd. Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
EP3906025A4 (en) 2019-01-04 2022-09-21 Columbia Care LLC CANNABINOID TOPICAL FORMULATIONS
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
EP3917505A4 (en) 2019-01-29 2022-11-02 Buzzelet Development And Technologies Ltd TERPENE ENRICHED CANNABINOID COMPOSITION AND METHOD OF TREATMENT FOR TREATING CONDITIONS AND/OR SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
US20210015740A1 (en) 2019-03-04 2021-01-21 Michael Harvey Greenspan Topical cannabinoid compositions, delivery systems, and uses for pain relief
KR20210153052A (ko) 2019-03-07 2021-12-16 일레라 테라퓨틱스 엘엘씨 자폐증 스펙트럼 장애와 관련된 클러스터 증상을 치료하기 위한 제제
WO2020183350A1 (en) 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Transdermal patch kit with transdermal dosage units
CN113811306A (zh) 2019-03-26 2021-12-17 温桑托尔公司 用于治疗周围神经病变的局部制剂
WO2020198883A1 (en) 2019-04-03 2020-10-08 Stratemeyer Trinczek Ely Nigel Transdermal medicament
US20200330379A1 (en) 2019-04-17 2020-10-22 Navinta NV, Inc. Non-oral cannabinoid formulation and method of treatment
AU2020264426A1 (en) 2019-05-01 2022-01-06 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
WO2020220141A1 (en) 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US20200345685A1 (en) 2019-05-02 2020-11-05 Christopher Ayo Otiko Topical application of medical cannabis
US20200345653A1 (en) 2019-05-02 2020-11-05 Kenda Hansen Transdermal Composition
US20200352849A1 (en) 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
CA3141993A1 (en) 2019-05-28 2020-12-03 Tech Swerve Llc Penetrating topical pain relief compositions and methods of use
US11026896B2 (en) 2019-06-18 2021-06-08 Dyve Biosciences, Inc. Transdermal penetrant formulations containing cannabidiol
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
BR112021026854A2 (pt) 2019-07-02 2022-03-29 Ellevet Sciences Extrato de cânhamo para tratamento da dor, câncer e epilepsia em animais
WO2021003467A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
JP2022546928A (ja) 2019-08-05 2022-11-10 シーエス メディカ アー／エス カンナビジオールを含む局所製剤、組成物の調製方法およびその使用
WO2021050429A1 (en) 2019-09-10 2021-03-18 Pureform Global, Inc. Topical composition for treatment of pain
JOP20220061A1 (ar) 2019-09-17 2023-01-30 Zynerba Pharmaceuticals Inc علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
US11951079B2 (en) 2019-10-03 2024-04-09 Kongkrit Chaiyasate Topical cannabidiol composition
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US11318093B2 (en) 2019-11-08 2022-05-03 Pac-Dent, Inc. Dental topical anesthetic gel
US20210145764A1 (en) 2019-11-15 2021-05-20 Brigham Young University Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
CA3158390A1 (en) 2019-11-20 2021-05-27 David Bradley Schmidt Combination cannabinoid-nad+ precursor formulation for treatment of inflammation and methods related thereto
US20210244680A1 (en) 2020-02-10 2021-08-12 Ghassan S. Kassab Wearable liposomal cannabidiol transdermal patch
GB2608314A (en) 2020-02-11 2022-12-28 Babak Ghalili Cannabinoid and menthol transdermal delivery systems and methods
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021177937A1 (en) 2020-03-02 2021-09-10 Babak Ghalili Cannabinoid and menthol compositions and methods
WO2021177940A1 (en) 2020-03-03 2021-09-10 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
CN115916184A (zh) 2020-04-20 2023-04-04 长矛治疗股份有限公司 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂
WO2021236782A1 (en) 2020-05-19 2021-11-25 Mig Usa, Llc Topical compositions and methods for treating pain
AU2021302977A1 (en) 2020-07-01 2023-02-09 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
JP2023537675A (ja) 2020-08-17 2023-09-05 パイク セラピューティクス インコーポレイテッド パーキンソン病の治療のための医薬組成物及びその治療方法
MX2023006561A (es) 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.

Also Published As

Publication number Publication date
CN114555068A (zh) 2022-05-27
WO2021074790A1 (en) 2021-04-22
EP4045024A4 (en) 2023-10-25
AU2020366147A1 (en) 2022-04-07
AU2020366147B2 (en) 2024-09-05
US20210106540A1 (en) 2021-04-15
CA3155181A1 (en) 2021-04-22
JP2022551730A (ja) 2022-12-13
US12097293B2 (en) 2024-09-24
EP4045024A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
MX2022004258A (es) Entrega transdermica de cannabidiol.
MX2022013410A (es) Metodos de tratamiento.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
WO2012109022A3 (en) Medical fluid delivery device programming
MX2022008236A (es) Metodos para administrar altas concentraciones de oxido nitrico.
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
MX2018013503A (es) Aparatos, métodos y sistemas para administrar medicamento utilizando kits de medicamento.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
MX2019014942A (es) Dispositivos de administracion de farmacos bioerosionables.
NZ769954A (en) Syringe devices for use in an emergency
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX2022004033A (es) Suministro transdermico de dronabinol.
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
EP4354455A3 (en) Techniques and devices providing adaptivity and personalization in diabetes treatment
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2017008000A (es) Sistema de inyeccion de un solo uso.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2023007826A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2023011948A (es) Entrega transdermica de cannabidiol:.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2018000257A (es) Dispositivo de suministro de un solo uso que tiene caracteristicas de seguridad.
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.